Your browser doesn't support javascript.
Global Excess Mortality during COVID-19 Pandemic: A Systematic Review and Meta-Analysis.
Shang, Weijing; Wang, Yaping; Yuan, Jie; Guo, Zirui; Liu, Jue; Liu, Min.
  • Shang W; School of Public Health, Peking University, Beijing 100191, China.
  • Wang Y; School of Public Health, Peking University, Beijing 100191, China.
  • Yuan J; School of Public Health, Peking University, Beijing 100191, China.
  • Guo Z; School of Public Health, Peking University, Beijing 100191, China.
  • Liu J; School of Public Health, Peking University, Beijing 100191, China.
  • Liu M; School of Public Health, Peking University, Beijing 100191, China.
Vaccines (Basel) ; 10(10)2022 Oct 12.
Article in English | MEDLINE | ID: covidwho-2071933
ABSTRACT

BACKGROUND:

Currently, reported COVID-19 deaths are inadequate to assess the impact of the pandemic on global excess mortality. All-cause excess mortality is a WHO-recommended index for assessing the death burden of COVID-19. However, the global excess mortality assessed by this index remains unclear. We aimed to assess the global excess mortality during the COVID-19 pandemic.

METHODS:

We searched PubMed, EMBASE, and Web of Science for studies published in English between 1 January 2020, and 21 May 2022. Cross-sectional and cohort studies that reported data about excess mortality during the pandemic were included. Two researchers independently searched the published studies, extracted data, and assessed quality. The Mantel-Haenszel random-effects method was adopted to estimate pooled risk difference (RD) and their 95% confidence intervals (CIs).

RESULTS:

A total of 79 countries from twenty studies were included. During the COVID-19 pandemic, of 2,228,109,318 individuals, 17,974,051 all-cause deaths were reported, and 15,498,145 deaths were expected. The pooled global excess mortality was 104.84 (95% CI 85.56-124.13) per 100,000. South America had the highest pooled excess mortality [134.02 (95% CI 68.24-199.80) per 100,000], while Oceania had the lowest [-32.15 (95% CI -60.53--3.77) per 100,000]. Developing countries had higher excess mortality [135.80 (95% CI 107.83-163.76) per 100,000] than developed countries [68.08 (95% CI 42.61-93.55) per 100,000]. Lower middle-income countries [133.45 (95% CI 75.10-191.81) per 100,000] and upper-middle-income countries [149.88 (110.35-189.38) per 100,000] had higher excess mortality than high-income countries [75.54 (95% CI 53.44-97.64) per 100,000]. Males had higher excess mortality [130.10 (95% CI 94.15-166.05) per 100,000] than females [102.16 (95% CI 85.76-118.56) per 100,000]. The population aged ≥ 60 years had the highest excess mortality [781.74 (95% CI 626.24-937.24) per 100,000].

CONCLUSIONS:

The pooled global excess mortality was 104.84 deaths per 100,000, and the number of reported all-cause deaths was higher than expected deaths during the global COVID-19 pandemic. In South America, developing and middle-income countries, male populations, and individuals aged ≥ 60 years had a heavier excess mortality burden.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10101702

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10101702